

# Monika Engelhardt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7374622/publications.pdf>

Version: 2024-02-01

169  
papers

5,173  
citations

101384

36  
h-index

106150

65  
g-index

172  
all docs

172  
docs citations

172  
times ranked

5655  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2017, 18, e206-e217.	5.1	394
2	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	1.7	289
3	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	5.1	254
4	A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. <i>Haematologica</i> , 2017, 102, 910-921.	1.7	187
5	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. <i>Haematologica</i> , 2014, 99, 232-242.	1.7	185
6	Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time. <i>Clinical Cancer Research</i> , 2015, 21, 1530-1536.	3.2	157
7	Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2007, 138, 330-337.	1.2	156
8	Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. <i>Haematologica</i> , 2016, 101, 1110-1119.	1.7	145
9	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
10	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> , 2014, 99, 984-996.	1.7	124
11	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	1.7	110
12	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	3.3	109
13	High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ Immunoselection. <i>Journal of Clinical Oncology</i> , 1999, 17, 2160-2160.	0.8	86
14	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018, 103, 1772-1784.	1.7	86
15	Chemotherapy safety and severe adverse events in cancer patients: Strategies to efficiently avoid chemotherapy errors in inpatient and outpatient treatment. <i>International Journal of Cancer</i> , 2009, 124, 722-728.	2.3	85
16	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	3.3	83
17	Cytogenetics of extramedullary manifestations in multiple myeloma. <i>British Journal of Haematology</i> , 2013, 161, 87-94.	1.2	81
18	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	3.3	81

#	ARTICLE	IF	CITATIONS
19	Elderly patients with multiple myeloma: towards a frailty approach?. <i>Current Opinion in Oncology</i> , 2017, 29, 315-321.	1.1	77
20	Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma Patients and Combination With the International Staging System Are Highly Predictive for Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 541-551.	0.2	72
21	Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). <i>Haematologica</i> , 2018, 103, 1422-1432.	1.7	70
22	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	3.3	68
23	Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. <i>European Journal of Haematology</i> , 2009, 83, 519-527.	1.1	67
24	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
25	Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma. <i>Leukemia and Lymphoma</i> , 2011, 52, 247-259.	0.6	63
26	<scp>CXCL</scp>12 and <scp>CXCR</scp>7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 179, 36-49.	1.2	63
27	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	2.8	62
28	Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. <i>Haematologica</i> , 2019, 104, 370-379.	1.7	53
29	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. <i>Leukemia and Lymphoma</i> , 2010, 51, 1424-1443.	0.6	49
30	Current developments in immunotherapy in the treatment of multiple myeloma. <i>Cancer</i> , 2018, 124, 2075-2085.	2.0	49
31	Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. <i>Haematologica</i> , 2020, 105, 1183-1188.	1.7	46
32	Defining the vulnerable patient with myeloma – a frailty position paper of the European Myeloma Network. <i>Leukemia</i> , 2020, 34, 2285-2294.	3.3	45
33	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. <i>Lancet Haematology</i> , 2022, 9, e143-e161.	2.2	44
34	Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. <i>Haematologica</i> , 2015, 100, 1340-1349.	1.7	43
35	Characterization of in vitro growth of multiple myeloma cells. <i>Experimental Hematology</i> , 2007, 35, 1550-1561.	0.2	42
36	Is immunotherapy here to stay in multiple myeloma?. <i>Haematologica</i> , 2017, 102, 423-432.	1.7	42

#	ARTICLE	IF	CITATIONS
37	Potent <i>in vitro</i> and <i>in vivo</i> activity of sorafenib in multiple myeloma: induction of cell death, $\downarrow$ CD138 $\downarrow$ downregulation and inhibition of migration through actin depolymerization. <i>British Journal of Haematology</i> , 2013, 161, 104-116.	1.2	40
38	Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. <i>Haematologica</i> , 2020, 105, 2872-2878.	1.7	40
39	Clinicians and patients perspectives on follow-up care and eHealth support after allogeneic hematopoietic stem cell transplantation: A mixed-methods contextual analysis as part of the SMILe study. <i>European Journal of Oncology Nursing</i> , 2020, 45, 101723.	0.9	37
40	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , 2021, 35, 1722-1731.	3.3	35
41	Posaconazole Therapeutic Drug Monitoring in the Real-Life Setting: A Single-Center Experience and Review of the Literature. <i>Pharmacotherapy</i> , 2013, 33, 1117-1125.	1.2	34
42	Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e160-e175.	0.2	31
43	State of the art therapy in multiple myeloma and future perspectives. <i>European Journal of Cancer</i> , 2006, 42, 1591-1600.	1.3	30
44	Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. <i>British Journal of Haematology</i> , 2017, 179, 586-597.	1.2	30
45	Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany. <i>Cancer Medicine</i> , 2020, 9, 8412-8422.	1.3	29
46	Primary (AL) Amyloidosis in Plasma Cell Disorders. <i>Oncologist</i> , 2006, 11, 824-830.	1.9	28
47	Therapeutic Drug Monitoring of Posaconazole in Hematology Patients: Experience with a New High-Performance Liquid Chromatography-Based Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4029-4032.	1.4	28
48	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. <i>Oncologist</i> , 2016, 21, 333-342.	1.9	28
49	Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. <i>Leukemia</i> , 2019, 33, 2710-2719.	3.3	28
50	Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. <i>Annals of Hematology</i> , 2012, 91, 1579-1586.	0.8	27
51	COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1264-1266.	1.4	27
52	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica</i> , 2021, 106, 2054-2065.	1.7	27
53	Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).. <i>Blood</i> , 2009, 114, 131-131.	0.6	27
54	Determination of the antifungal agent posaconazole in human serum by HPLC with parallel column-switching technique. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 2493-2498.	1.2	26

#	ARTICLE	IF	CITATIONS
55	Prognostic Risk Factor Evaluation in Patients With Relapsed or Refractory Multiple Myeloma Receiving Lenalidomide Treatment: Analysis of Renal Function by eGFR and of Additional Comorbidities by Comorbidity Appraisal. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 38-48.	0.2	26
56	Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 764-768.	0.5	26
57	Intratumoral Injection of Human Multiple Myeloma Cells in NOD/SCID IL-2R $\beta$ (Null) Mice Mimics Human Myeloma and Serves as a Valuable Tool for the Development of Anticancer Strategies. <i>PLoS ONE</i> , 2013, 8, e79939.	1.1	23
58	Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia. <i>Haematologica</i> , 2020, 105, 1285-1293.	1.7	22
59	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	1.7	22
60	Management of Multiple Myeloma in Pregnancy: Strategies for a Rare Challenge. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 190-197.	0.2	21
61	Preclinical models of multiple myeloma: a critical appraisal. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, S111-S123.	1.4	21
62	Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation. <i>Annals of Hematology</i> , 2012, 91, 287-289.	0.8	19
63	Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials. <i>Leukemia and Lymphoma</i> , 2018, 59, 2692-2699.	0.6	19
64	Avoiding chemotherapy prescribing errors: Analysis and innovative strategies. <i>Cancer</i> , 2019, 125, 1547-1557.	2.0	19
65	Allogeneic Stem Cell Transplant Versus Tandem High-Dose Melphalan for Front-Line Treatment of Deletion 13q14 Myeloma – An Interim Analysis of the German DSMM V Trial. <i>Blood</i> , 2009, 114, 51-51.	0.6	19
66	Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patients. <i>Cancer</i> , 2020, 126, 3504-3515.	2.0	18
67	Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma. <i>Anticancer Research</i> , 2012, 32, 2031-4.	0.5	18
68	Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit) <i>TJ ETQq0 0 0 rgBT7/Overloadk 10 Tf 50</i>		
69	Geriatric assessments and frailty scores in multiple myeloma patients. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 648-657.	1.1	16
70	Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth – the SMILE study. <i>Supportive Care in Cancer</i> , 2021, 29, 8045-8057.	1.0	15
71	Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML <i>in vitro</i> and prolongs survival <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 21153-21166.	0.8	15
72	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2006-2011.	0.6	14

#	ARTICLE	IF	CITATIONS
73	Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study. <i>Supportive Care in Cancer</i> , 2018, 26, 833-841.	1.0	14
74	Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. <i>Haematologica</i> , 2021, 106, 875-880.	1.7	14
75	Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. <i>BMC Nephrology</i> , 2021, 22, 32.	0.8	14
76	Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers. <i>Leukemia and Lymphoma</i> , 2017, 58, 1849-1858.	0.6	13
77	Lenalidomide, Adriamycin and Dexamethasone (RAD) As An Induction Regimen In Newly Diagnosed Multiple Myeloma – Interim Results From a German Multicenter Phase II Trial. <i>Blood</i> , 2013, 122, 1987-1987.	0.6	13
78	Prevalence of Iron Overload Vs Iron Deficiency in Multiple Myeloma: Resembling or Different From MDS and Stem Cell Transplant (SCT) Patients?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 671-680.e3.	0.2	12
79	Time from first symptom onset to the final diagnosis of multiple myeloma (MM) – possible risks and future solutions: retrospective and prospective – Deutsche Studiengruppe MM (DSMM) and – European Myeloma Network (EMN) analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 875-886.	0.6	12
80	Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation. <i>Journal of Geriatric Oncology</i> , 2021, 12, 521-530.	0.5	12
81	Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 55.	1.7	12
82	160 years of multiple myeloma: Progress and challenges. <i>European Journal of Cancer</i> , 2006, 42, 1507-1509.	1.3	11
83	Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 1057-1061.	0.6	11
84	Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors. <i>Cancers</i> , 2021, 13, 4320.	1.7	11
85	Pomalidomide. <i>Recent Results in Cancer Research</i> , 2014, 201, 359-372.	1.8	11
86	Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma. <i>Anticancer Research</i> , 2009, 29, 4745-50.	0.5	11
87	Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?. <i>Haematologica</i> , 2016, 101, 1276-1278.	1.7	10
88	Paving the Way for Dose Banding of Chemotherapy: An Analytical Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 484-493.	2.3	10
89	Dynamic prediction: A challenge for biostatisticians, but greatly needed by patients, physicians and the public. <i>Biometrical Journal</i> , 2020, 62, 822-835.	0.6	10
90	Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma. <i>Haematologica</i> , 2020, 105, e523.	1.7	10

#	ARTICLE	IF	CITATIONS
91	Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 953-963.	0.9	9
92	Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort. <i>Cancer</i> , 2021, 127, 3422-3436.	2.0	9
93	The impact of pulmonary function in patients undergoing autologous stem cell transplantation. <i>Blood Advances</i> , 2021, 5, 4327-4337.	2.5	9
94	Incidence of monoclonal B-cell disease in siblings of patients with multiple myeloma. <i>Haematologica</i> , 2006, 91, 274-6.	1.7	9
95	Early and mature endothelial progenitors and VEGFR2+-cells in multiple myeloma: Association with disease characteristics and variation in different cell compartments. <i>Leukemia Research</i> , 2011, 35, 1265-1268.	0.4	8
96	From <scp>CLL</scp> to Multiple Myeloma – Spleen Tyrosine Kinase (<scp>SYK</scp>) influences multiple myeloma cell survival and migration. <i>British Journal of Haematology</i> , 2016, 174, 985-989.	1.2	8
97	Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. <i>Leukemia Research</i> , 2020, 98, 106454.	0.4	8
98	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	1.1	8
99	Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 48220-48230.	0.8	8
100	Intensive Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation During a 10-Year Period in 64 Patients with Germ Cell Tumor. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 355-365.	2.0	7
101	Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: A single center analysis and review of the literature. <i>Leukemia and Lymphoma</i> , 2007, 48, 2255-2260.	0.6	7
102	Analysis of survival by tumor response: have we learnt any better?. <i>Annals of Hematology</i> , 2015, 94, 1615-1616.	0.8	7
103	Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment. <i>Haematologica</i> , 2020, 105, 859-861.	1.7	7
104	Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany. <i>Journal of Medical Economics</i> , 2021, 24, 114-122.	1.0	7
105	Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 708231.	1.3	7
106	Bortezomib Retreatment in Relapsed Multiple Myeloma (MM): Results from a Binational, Multicenter Retrospective Survey. <i>Blood</i> , 2008, 112, 2775-2775.	0.6	7
107	Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1045-1055.	1.2	7
108	Multiple Myeloma and Second Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 98-101.	0.2	6

#	ARTICLE	IF	CITATIONS
109	The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. <i>European Journal of Haematology</i> , 2017, 99, 449-458.	1.1	6
110	Cast Nephropathy and Deceptively Low Absolute Serum Free Light Chain Levels: Resolution of a Challenging Case and Systematic Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e1-e7.	0.2	6
111	Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions. <i>Haematologica</i> , 2018, 103, 755-758.	1.7	6
112	Pomalidomide. <i>Recent Results in Cancer Research</i> , 2018, 212, 169-185.	1.8	6
113	Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials. <i>European Journal of Haematology</i> , 2019, 103, 255-267.	1.1	6
114	Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM. <i>Cancers</i> , 2021, 13, 1322.	1.7	6
115	The 3' Untranslated Region of the Cyclin B mRNA Is Not Sufficient to Enhance the Synthesis of Cyclin B during a Mitotic Block in Human Cells. <i>PLoS ONE</i> , 2013, 8, e74379.	1.1	6
116	APC/CCdh1 regulates the balance between maintenance and differentiation of hematopoietic stem and progenitor cells. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 369-380.	2.4	5
117	Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient. <i>Haematologica</i> , 2020, 105, e138-e140.	1.7	5
118	Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 774-774.	0.6	5
119	Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule. <i>Leukemia and Lymphoma</i> , 2018, 59, 1722-1725.	0.6	4
120	Kidney embolization induces prompt organ response in a 86-year-old patient with MGRS-related AL amyloidosis. <i>Hemodialysis International</i> , 2019, 23, E59-E64.	0.4	4
121	Interdisciplinary approach to multiple myeloma – time to diagnosis and warning signs. <i>Leukemia and Lymphoma</i> , 2021, 62, 891-898.	0.6	4
122	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. <i>Cancer</i> , 2021, 127, 3413-3421.	2.0	4
123	Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience. <i>HemaSphere</i> , 2021, 5, e597.	1.2	4
124	Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study. <i>Blood</i> , 2018, 132, 2288-2288.	0.6	4
125	The Revised Myeloma Comorbidity Index (R-MCI) As a Promising Approach for Predicting Overall (OS)- and Progression-Free (PFS) Survival and Optimizing Therapy Strategies in Multiple Myeloma (MM) Patients (pts) - Comparative Analysis of 5 Comorbidity Indices (CI), Including Retro- and Prospective Applicability. <i>Blood</i> , 2019, 134, 3474-3474.	0.6	4
126	Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptosed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 2111-2111.	0.6	4



#	ARTICLE	IF	CITATIONS
127	Does Colorectal Cancer in Ulcerative Colitis Patients Constitute a Risk for Chemotherapy Refractoriness? A Systemic Approach by Detailed Analysis via the Electronic Tumor Base Documentation System. <i>Onkologie</i> , 2011, 34, 688-694.	1.1	3
128	Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?. <i>Haematologica</i> , 2019, 104, 2128-2131.	1.7	3
129	Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures. <i>BMC Cancer</i> , 2021, 21, 173.	1.1	3
130	Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 529-542.	1.1	3
131	Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study. <i>Blood</i> , 2019, 134, 3480-3480.	0.6	3
132	Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM Xla Trial. <i>Blood</i> , 2008, 112, 2776-2776.	0.6	3
133	Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase Ila Study. <i>Blood</i> , 2013, 122, 1951-1951.	0.6	3
134	Carfilzomib. <i>Recent Results in Cancer Research</i> , 2018, 212, 265-283.	1.8	2
135	Dapsone-Induced Hemolytic Anemia in Multiple Myeloma: Case Report of Various Differential Diagnoses. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e821-e825.	0.2	2
136	Coincidence of Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) in One Patient: An Exceptional or Common Event? Summary of 4 Cases at a Single Center.. <i>Blood</i> , 2006, 108, 4980-4980.	0.6	2
137	A Multi-Center Analysis of Renal Impairment as a Potential Prognostic Factor: Analysis in Multiple Myeloma Patients Treated with Standard or High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 4830-4830.	0.6	2
138	Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial. <i>Blood</i> , 2021, 138, 1662-1662.	0.6	2
139	Proteasome inhibition: the dawn of novel therapies in multiple myeloma. <i>Haematologica</i> , 2022, 107, 1018-1019.	1.7	2
140	Empirical caspofungin therapy in clinical practice for suspected invasive fungal disease in adults with acute lymphoblastic leukaemia. <i>Mycoses</i> , 2015, 58, 76-81.	1.8	1
141	Diffuse large B cell lymphoma (DLBCL): bilateral vanishing tibiae. <i>Annals of Hematology</i> , 2018, 97, 1497-1500.	0.8	1
142	GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 199-206.	0.7	1
143	Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab. <i>Annals of Hematology</i> , 2021, 100, 1637-1640.	0.8	1
144	Bortezomib Retreatment in Relapsed Multiple Myeloma - A Retrospective Multicenter Survey.. <i>Blood</i> , 2007, 110, 2720-2720.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Antitumor Activity of Novel Anti-MM Agents and Combinations, the Proteasome Inhibitor Bortezomib and Multikinase Inhibitor Sorafenib, Both Applied as Monotherapy and in Combination in NOD/SCID-IL2-Receptor-Gamma-chain <sup>-/-</sup> /NSG Mice Using an Intratibial Tumor Dissemination approach. Blood, 2009, 114, 4912-4912.	0.6	1
146	Rituximab Plus Bendamustine (R-B) Treatment in Patients with Aggressive Large B-Cell Lymphoma (LBCL): Response and Tolerability - a Single Institution Experience. Blood, 2010, 116, 4900-4900.	0.6	1
147	Exosomes Secreted by Multiple Myeloma Cell Lines (MMCLs) and Bone Marrow Stromal Cells (BMSCs) Reciprocally Modulate Cell Adhesion and Impact on MM Cell Migration and Bortezomib-Induced Apoptosis. Blood, 2014, 124, 5141-5141.	0.6	1
148	Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD). Blood, 2015, 126, 4260-4260.	0.6	1
149	Dose Reduction of Thalidomide in Multiple Myeloma: A Feasible Option without Reducing of Efficacy. Blood, 2005, 106, 5129-5129.	0.6	1
150	Ordering Errors Were Identified. Deutsches Arzteblatt International, 2010, 107, 557-8; author reply 559-60.	0.6	1
151	The Tumor Suppressor APC/CCdh1 and Its Role in Replication Stress and the Origin of Genomic Instability. Blood, 2013, 122, 2489-2489.	0.6	1
152	Favourable outcomes of double-hit/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and upfront autologous stem cell transplantation: a single-centre retrospective experience. British Journal of Haematology, 0, , .	1.2	1
153	In search of the optimal proteasome inhibitor. How, when and for whom?. Haematologica, 2021, 106, 2539-2541.	1.7	0
154	Elektronische Verordnungssysteme in der Hämatologie und Onkologie/CPOE. Springer Reference Medizin, 2021, , 1-8.	0.0	0
155	Mild Renal Impairment as a Potential Prognostic Factor in Patients with Solid Tumors and Hematological Malignancies. Blood, 2005, 106, 2250-2250.	0.6	0
156	Improved Prediction of Kidney Disease by Estimating Renal Function: Use in Multiple Myeloma Patients Treated with Standard Versus High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation. Blood, 2006, 108, 5497-5497.	0.6	0
157	Assessment of the Culture Requirements for Optimal In Vitro Growth and Survival of Multiple Myeloma (MM) Cells. Blood, 2006, 108, 3513-3513.	0.6	0
158	Peripheral Blood, Cord Blood and Bone Marrow Cells Sorted into SP+, CD34+ and SP <sup>+</sup> Cells Are Distinct in Their ABCG2 and MDR1 Expression Levels, Which Are Most Increased in SP+ Cells and Substantially Decline after In Vitro Culture and Terminal Cell Differentiation. Blood, 2006, 108, 4154-4154.	0.6	0
159	Efficacy and Tolerability of Lenalidomide/Dexamethasone in Intensively Pretreated Myeloma Patients: Experiences from the German Named Patient Program. Blood, 2007, 110, 4834-4834.	0.6	0
160	Analysis of Efficacy, Safety and Costs of Systemic Antifungal Agents in 159 Consecutive High-Risk Cancer Patients for the Establishment of Standardized Guidelines. Blood, 2008, 112, 1313-1313.	0.6	0
161	Detection of Renal Impairment (RI) as One Specific Comorbidity Factor in Multiple Myeloma (MM) Patients: Multi-Center Study in 198 Consecutive Patients. Blood, 2008, 112, 2372-2372.	0.6	0
162	Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma. Blood, 2008, 112, 974-974.	0.6	0

#	ARTICLE	IF	CITATIONS
163	In Vitro Assessment of Anti-Multiple Myeloma (MM)-Agents On Various MM-Cell Lines (MMCLs) with Use of Bortezomib, Sorafenib, Thalidomide, Lenalidomide and EpiGalloCatechin-3-Gallate (EGCG) Demonstrates to Be a Valuable Tool for the Thorough Analysis and Discovery of Innovative Anti-MM-Agents.. Blood, 2009, 114, 4922-4922.	0.6	0
164	Invasive Mycoses in High-Risk Cancer Patients - a Prospective Analysis of Clinical Parameters, Side Effects, Drug Interactions and Costs for the Safe and Economically Appropriate Use of Systemic Antifungal Agents.. Blood, 2009, 114, 2487-2487.	0.6	0
165	Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.. Blood, 2009, 114, 4945-4945.	0.6	0
166	Downregulation of the Cell-Cycle Regulating Ubiquitin-Ligase APC/CCdh1 May Contribute to the Differentiation Block of AML1/Eto Positive AML.. Blood, 2009, 114, 5045-5045.	0.6	0
167	Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis. Blood, 2016, 128, 5979-5979.	0.6	0
168	Avoiding Errors in Chemotherapy. Deutsches A&#x0308;rzteblatt International, 2017, 114, 224.	0.6	0
169	Targeting mitotic exit in solid tumors. American Journal of Cancer Research, 2021, 11, 3698-3710.	1.4	0